Peer-reviewedCC BY-NC-NDInternal Medicine
Peritoneal mesothelioma showing a remarkable response to nivolumab plus ipilimumab in a patient with Lynch syndrome: A case report and literature review
Abstract
Peritoneal mesothelioma is a rare tumor, with few reports describing microsatellite instability. Lynch syndrome is a hereditary cancer predisposition syndrome commonly associated with colorectal and endometrial cancers. However, reports of peritoneal mesothelioma are rare. We herein describe a 48-year-old patient diagnosed with peritoneal mesothelioma and Lynch syndrome through comprehensive genomic profiling at the time of recurrence. Subsequent treatment with nivolumab plus ipilimumab resulted in a remarkable response. This case highlights the utility of genomic profiling during cancer treatment in uncovering unexpected hereditary cancer syndromes and thus guiding the selection of effective therapies.
Related
- 36 Baseline systemic immune profiles predict prognosis and differential benefit from ipilimumab intensification in relapsed mesothelioma (Bio-IFCT-1501 MAPS2 trial)
- Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer
- 484 Phase II neoadjuvant study of nivolumab alone and in combination with relatlimab or ipilimumab in resectable head and neck cancer
- Marked Response to Nivolumab Plus Ipilimumab After the Failure of Two Prior Immune Checkpoint Inhibitor–Based Regimens Including CTLA-4 Blockade in Advanced Hepatocellular Carcinoma
- Neoadjuvant pepinemab in combination with nivolumab and/or ipilimumab in resectable metastatic melanoma: a pilot biomarker-driven trial
BibTeX
@article{ueda2026peritoneal,
title = {{Peritoneal mesothelioma showing a remarkable response to nivolumab plus ipilimumab in a patient with Lynch syndrome: A case report and literature review}},
author = {Yuko Ueda and Rei Fukuda and Takayuki Ando and Yurika Nakayama and Iori Motoo and Shinya Kajiura and Isaya Hashimoto and Toru Watanabe and Takashi Minamisaka and Kenichi Hirabayashi and Yukihide Kanemitsu and Tsutomu Fujii and Ichiro Yasuda},
journal = {Internal Medicine},
year = {2026},
month = jul,
doi = {10.2169/internalmedicine.7052-25},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7052-25/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Peritoneal mesothelioma showing a remarkable response to nivolumab plus ipilimumab in a patient with Lynch syndrome: A case report and literature review
AU - Yuko Ueda
AU - Rei Fukuda
AU - Takayuki Ando
AU - Yurika Nakayama
AU - Iori Motoo
AU - Shinya Kajiura
AU - Isaya Hashimoto
AU - Toru Watanabe
AU - Takashi Minamisaka
AU - Kenichi Hirabayashi
AU - Yukihide Kanemitsu
AU - Tsutomu Fujii
AU - Ichiro Yasuda
PY - 2026
DA - 2026/07/25
JO - Internal Medicine
DO - 10.2169/internalmedicine.7052-25
UR - https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7052-25/_article
AB - Peritoneal mesothelioma is a rare tumor, with few reports describing microsatellite instability. Lynch syndrome is a hereditary cancer predisposition syndrome commonly associated with colorectal and endometrial cancers. However, reports of peritoneal mesothelioma are rare. We herein describe a 48-year-old patient diagnosed with peritoneal mesothelioma and Lynch syndrome through comprehensive genomic profiling at the time of recurrence. Subsequent treatment with nivolumab plus ipilimumab resulted in a remarkable response. This case highlights the utility of genomic profiling during cancer treatment in uncovering unexpected hereditary cancer syndromes and thus guiding the selection of effective therapies.
SN - 1349-7235
SN - 0918-2918
ER -